About: Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis
Creator	Azevedo, Vasco Miyoshi, Anderson Lemos, Luísa Moraes, Kátia Caetano Faria, Ana Cara, Denise De Azevedo, Marcela Diniz Luerce, Tessalia Gomes-Santos, Ana Leblanc, Jean Moreira, Thais Nogueira Cruz, Déborah Pereira, Vanessa Santos Rocha, Clarissa Sousa, Adna
source	Medline; PMC
abstract	BACKGROUND: Many probiotic bacteria have been described as promising tools for the treatment and prevention of inflammatory bowel diseases (IBDs). Most of these bacteria are lactic acid bacteria, which are part of the healthy human microbiota. However, little is known about the effects of transient bacteria present in normal diets, including Lactococcus lactis. METHODS: In the present study, we analysed the immunomodulatory effects of three L. lactis strains in vitro using intestinal epithelial cells. L. lactis NCDO 2118 was administered for 4 days to C57BL/6 mice during the remission period of colitis induced by dextran sodium sulphate (DSS). RESULTS: Only one strain, L. lactis NCDO 2118, was able to reduce IL-1β-induced IL-8 secretion in Caco-2 cells, suggesting a potential anti-inflammatory effect. Oral treatment using L. lactis NCDO 2118 resulted in a milder form of recurrent colitis than that observed in control diseased mice. This protective effect was not attributable to changes in secretory IgA (sIgA); however, NCDO 2118 administration was associated with an early increase in IL-6 production and sustained IL-10 production in colonic tissue. Mice fed L. lactis NCDO 2118 had an increased number of regulatory CD4(+) T cells (Tregs) bearing surface TGF-β in its latent form (Latency-associated peptide-LAP) in the mesenteric lymph nodes and spleen. CONCLUSIONS: Here, we identified a new probiotic strain with a potential role in the treatment of IBD, and we elucidated some of the mechanisms underlying its anti-inflammatory effect.
has issue date	2014-07-29(xsd:dateTime)
bibo:doi	10.1186/1757-4749-6-33
bibo:pmid	25110521
has license	cc-by
sha1sum (hex)	3128ce331b8e280214991a3c775c895045ccfa70
schema:url	https://doi.org/10.1186/1757-4749-6-33
resource representing a document's title	Anti-inflammatory effects of Lactococcus lactis NCDO 2118 during the remission period of chemically induced colitis
has PubMed Central identifier	PMC4126083
has PubMed identifier	25110521
schema:publication	Gut Pathog
resource representing a document's body	covid:3128ce331b8e280214991a3c775c895045ccfa70#body_text
is schema:about of	covid:arg/3128ce331b8e280214991a3c775c895045ccfa70 named entity 'human microbiota' named entity 'inflammatory bowel diseases' named entity 'normal' named entity 'bacteria' named entity 'Lactococcus lactis' named entity 'bacteria' named entity 'inflammatory bowel diseases' named entity 'Lactococcus lactis' named entity 'muscle' named entity 'anti-inflammatory effect' named entity 'histological' named entity 'IBD' named entity 'inflammatory mediators' named entity 'PBS' named entity 'Bifidobacterium longum' named entity 'L. lactis' named entity 'control group' named entity 'mice' named entity 'DCs' named entity 'probiotics' named entity 'room temperature' named entity 'macroscopic' named entity 'RPMI' named entity 'mice' named entity 'IL-10' named entity 'supernatant' named entity 'lymphocytes' named entity 'commensals' named entity 'animal research' named entity 'DCs' named entity 'antibody' named entity 'mesenteric lymph nodes' named entity 'IL-1β' named entity 'probiotics' named entity 'IL-8' named entity 'abscesses' named entity 'ulcerative colitis' named entity 'Bifidobacterium breve' named entity 'CD25' named entity 'lactic acid bacteria' named entity 'diarrhea' named entity 'CD25' named entity 'DCs' named entity 'MOI' named entity 'assay' named entity 'weight loss' named entity 'Caco-2 cells' named entity 'TGF-β' named entity 'sulphate' named entity 'faecal pellet' named entity 'IBD' named entity 'cytokine' named entity 'Caco-2' named entity 'L. lactis' named entity 'Biotechnology' named entity 'weight gain' named entity 'lymphoid' named entity 'CD11c' named entity 'Th17 cells' named entity 'probiotic' named entity 'cytokines' named entity 'colitis' named entity 'Streptavidin' named entity 'supernatants' named entity 'bacterial translocation' named entity 'IgA production'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software